Therapeutic polymorphs of a GABA-A alpha-5 inverse agonist and pamoate formulations of the same
申请人:Merck & Co., Inc.
公开号:US20010049439A1
公开(公告)日:2001-12-06
There is disclosed 3-(5-methylisoxazol-3-yl)-6-(1-methyl-1,2,3-triazol-4-yl)methyloxy-1,2,4-triazolo[3,4-a]phthalazine in the form of a dihydrate, a dehydrate of the dihydrate and a pentahydrate, pharmaceutical compositions comprising the forms, the use of the forms for enhancing cognition, processes for producing the forms, their incorporation in pharmaceutical compositions comprising pamoate ions and the use of such ions for solubilizing neutral molecules.
披露了3-(5-甲基异噁唑-3-基)-6-(1-甲基-1,2,3-三唑-4-基)甲氧基-1,2,4-三唑并且以二水合物、二水合物的脱水物和五水合物的形式存在,包括这些形式的药物组合物,用于增强认知的形式的使用,生产这些形式的过程,它们在包含帕莫酸离子的药物组合物中的应用以及使用这些离子溶解中性分子。